Back to Search
Start Over
Studies from Yamagata Prefectural Central Hospital Yield New Information about Lung Cancer (Nivolumab Therapy In Lung Cancer Associated With Igg4-related Disease).
Studies from Yamagata Prefectural Central Hospital Yield New Information about Lung Cancer (Nivolumab Therapy In Lung Cancer Associated With Igg4-related Disease).
- Source :
- Immunotherapy Weekly; 2024, p1904-1904, 1p
- Publication Year :
- 2024
-
Abstract
- A study conducted at Yamagata Prefectural Central Hospital in Japan explored the use of nivolumab therapy in a 75-year-old man with lung cancer and IgG4-related disease (IgG4-RD). The patient was treated with nivolumab and low-dose prednisolone for 15 months, during which time the IgG4-RD did not relapse and no adverse events occurred. The researchers concluded that anti-programmed cell death protein-1 antibody (nivolumab) may be safely used in lung cancer patients with IgG4-RD, alongside low-dose steroids. This research has been peer-reviewed and published in Internal Medicine. [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 10908625
- Database :
- Supplemental Index
- Journal :
- Immunotherapy Weekly
- Publication Type :
- Periodical
- Accession number :
- 175606718